Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

Phase 2 Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer with Actionable Genomic Alterations Ended

2024-511449-21-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 2021-03-25
A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended

2023-509513-36-00 Melanoma (Stage III and IV) 2021-03-24
Spontaneous Retinal Arterial Pulsations (SRAPs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVOs) in patients treated o… Ended

2024-516681-10-01 central retinal vein occlusions 2021-03-24
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P… Ended

2023-509449-10-00 Squamous cell carcinoma of the head and neck (SCCHN) 2021-03-16
ADMSC-fib safety and efficacy in patients with chronico wounds Ended

2024-518789-29-00 chronic wounds 2021-03-15
“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatini… Ended

2023-508001-25-00 Metastatic Thymic Carcinoma & B3-thymoma. 2021-03-15
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects… Ended

2024-515534-32-00 Subjects with nummular eczema 2021-03-15
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Su… Ended

2024-520057-20-00 Plaque Psoriasis 2021-03-09
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis Ended

2024-513075-40-00 Relapsed or refractory AL amyloidosis 2021-03-01
Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended

2023-504944-32-00 Non-clear Cell Renal Cell Carcinoma 2021-02-17
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) Ended

2024-511140-37-00 OligoRecurrent prostate cancer 2021-02-12
Randomized trial evaluating adapted chemotherapy in patients with squamous carcinoma Ended

2024-512456-38-00 locally advanced squamous cell carcinoma 2021-02-04
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outc… Ended

2024-510663-34-00 Influenza, Human 2021-01-29
This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use… Ended

2023-503771-13-00 Classic Congenital Adrenal Hyperplasia 2021-01-28
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Ended

2024-512652-38-00 Cutaneous Squamous Cell Carcinoma 2021-01-25
Study of Cemiplimab in Patients with type of skin cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Ended

2022-500811-37-00 Stage II to IV cutaneous squamous cell carcinoma 2021-01-19
Mogamulizumab Every 4 Week dosing in Participants with R/R CTCL Ended

2024-515921-27-00 Mycosis fungoides/Sezary syndrome recurrent 2021-01-13
This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of… Ended

2023-503770-21-00 Classic Congenital Adrenal Hyperplasia 2021-01-05
A Clinical Study to Investigate the Efficacy and Safety of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B … Ended

2023-506763-33-00 Hepatitis B and Hepatitis D Viral Co-infection 2020-12-18
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-… Ended

2023-503519-13-00 Advanced Hepatocellular Carcinoma 2020-12-14
Study to evaluate the effect and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes Ended

2024-513560-26-00 Recent onset Type 1 Diabetes 2020-12-10
TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended

2023-505894-33-00 Lung Cancer, Non-Small Cell 2020-11-25
Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized … Ended

2022-502745-98-00 Esophageal and gastric cancer 2020-11-17
Efficacy of immunotherapy in combination with a drug in patients with advanced mucosal cancer of different locations that has progress. Ended

2023-510320-71-00 Squamous cell carcinoma of vulva/vagina 2020-10-27